Roche's combo therapy reduces risk of liver cancer returning but raises safety questions: #AACR23
ORLANDO — Roche’s Tecentriq-Avastin combination, already approved for one indication, reduced the risk of cancer recurrence among patients after they received surgery for an early-stage liver cancer.
The Phase III trial could change the landscape of treatment for patients in the early stages of hepatocellular carcinoma, or HCC, according to Genentech, a unit of Roche. But the results raised potentially worrying safety signals as well, including two patient deaths related to the combination, though experts said the data were too early to reach firm conclusions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.